Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 451

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 451
---
 | ​ | ​ | ​ |  200,533 | ​ | ​ |
| ​ | Change in fair value             | ​ | ​ | ​ | ​ | -141,971 | ​ | ​ |
| ​ | Fair value at September 30, 2024 | ​ | ​ | ​ | $ |   58,562 | ​ | ​ |

NOTE 11. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events other than the below that would have required adjustment or disclosure in the financial statements. On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to amend the consideration to be paid in the Transactions to consist of 17.5 million shares of ParentCo’s common stock at $10.00 per share value. On October 30, 2024, as a result of Gaius acquisition of Columbass, Columbass resigned as managing member of the Sponsor, and Iris Equity Holdings LLC, an affiliate of Gaius, was appointed as managing member of the Sponsor. On October 31, 2024, the PIPE Equity Subscription Agreement was amended to decrease the PIPE Investor’s committed purchase of PIPE Shares from 2,500,000 to 1,500,000, decrease the PIPE Equity Investment from $25,000,000 to $15,000,000. On November 1, 2024, the Company obtained additional advances under the Liminatus unsecured promissory note of $300,000, which resulted in a total outstanding principal balance of $3,418,500. On November 5, 2024, $28,672 was deposited into the Trust Account representing an Extension Payment. The Extension Payment was deposited from the Company’s operating account and is Due from Sponsor. On November 27, 2024, the Liminatus unsecured promissory note was amended and restated to increase the aggregate principal amount to up to $5,000,000.

F-25

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
On December 2, 2024 and January 7, 2025, the Company obtained additional advances under the Liminatus unsecured promissory note in the total amount